AU2021316119A1 - Anti-connexin antibody formulations - Google Patents

Anti-connexin antibody formulations Download PDF

Info

Publication number
AU2021316119A1
AU2021316119A1 AU2021316119A AU2021316119A AU2021316119A1 AU 2021316119 A1 AU2021316119 A1 AU 2021316119A1 AU 2021316119 A AU2021316119 A AU 2021316119A AU 2021316119 A AU2021316119 A AU 2021316119A AU 2021316119 A1 AU2021316119 A1 AU 2021316119A1
Authority
AU
Australia
Prior art keywords
antibody
formulation
pharmaceutical formulation
seq
histidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021316119A
Other languages
English (en)
Inventor
Yanfeng Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alamab Therapeutics Inc
Original Assignee
Alamab Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alamab Therapeutics Inc filed Critical Alamab Therapeutics Inc
Publication of AU2021316119A1 publication Critical patent/AU2021316119A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
AU2021316119A 2020-07-31 2021-07-30 Anti-connexin antibody formulations Pending AU2021316119A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063059502P 2020-07-31 2020-07-31
US63/059,502 2020-07-31
PCT/US2021/044043 WO2022026914A1 (en) 2020-07-31 2021-07-30 Anti-connexin antibody formulations

Publications (1)

Publication Number Publication Date
AU2021316119A1 true AU2021316119A1 (en) 2023-03-02

Family

ID=80002768

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021316119A Pending AU2021316119A1 (en) 2020-07-31 2021-07-30 Anti-connexin antibody formulations

Country Status (9)

Country Link
US (2) US11912764B2 (cg-RX-API-DMAC7.html)
EP (1) EP4188544A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023537316A (cg-RX-API-DMAC7.html)
KR (1) KR20230042744A (cg-RX-API-DMAC7.html)
CN (1) CN116234576A (cg-RX-API-DMAC7.html)
AU (1) AU2021316119A1 (cg-RX-API-DMAC7.html)
CA (1) CA3190474A1 (cg-RX-API-DMAC7.html)
IL (1) IL300245A (cg-RX-API-DMAC7.html)
WO (1) WO2022026914A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116854816A (zh) * 2018-04-02 2023-10-10 阿拉玛布治疗学股份有限公司 连接蛋白43抗体及其用途
AU2020219112A1 (en) * 2019-02-04 2021-08-26 Alamab Therapeutics, Inc. Connexin 43 antibodies and use thereof
IL300245A (en) 2020-07-31 2023-03-01 Alamab Therapeutics Inc Anti-connexin antibody formulations
US20250277017A1 (en) * 2022-04-29 2025-09-04 Board Of Regents, The University Of Texas System Compositions and methods for treating eye diseases
WO2025006774A1 (en) * 2023-06-30 2025-01-02 Alamab Therapeutics, Inc. Method of treating osteoarthritis
EP4761813A1 (en) * 2023-08-14 2026-06-24 Alamab Therapeutics, Inc. Method of treating stroke
WO2025245485A1 (en) * 2024-05-24 2025-11-27 Alamab Therapeutics, Inc. Method of treating bone cancers

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101573131B (zh) 2005-02-03 2017-12-01 科达治疗有限公司 抗‑连接蛋白化合物及其治疗应用
EP1865986B1 (en) * 2005-03-08 2016-02-17 Pfizer Products Inc. Anti-ctla-4 antibody compositions
WO2009148613A1 (en) 2008-06-04 2009-12-10 Coda Therapeutics, Inc. Treatment of pain with gap junction modulation compounds
CN102413839A (zh) * 2009-03-06 2012-04-11 医学免疫有限责任公司 人源化抗cd19抗体制剂
US8956868B2 (en) 2010-12-27 2015-02-17 Lsip, Llc Induced pluripotent stem cells produced with a connexin inhibitor and a TGF-β signaling inhibitor
WO2015027120A1 (en) 2013-08-21 2015-02-26 Jiang Jean X Compositions and methods for targeting connexin hemichannels
US9493552B2 (en) 2013-11-15 2016-11-15 China Synthetic Rubber Corporation Therapeutic biologic for treatment of hepatocellular carcinoma
WO2016029191A2 (en) 2014-08-22 2016-02-25 Auckland Uniservices Limited Channel modulators
EP3394099A4 (en) * 2015-12-22 2019-11-27 Merck Sharp & Dohme Corp. Formulations of Manipulated Anti- IL-10 Antibodies
BR112018017031A2 (pt) * 2016-02-23 2019-01-22 Sesen Bio Inc formulações de antagonista de il-6 e usos das mesmas
AU2017224122B2 (en) * 2016-02-26 2024-04-11 The Board Of Regents Of The University Of Texas System Connexin (Cx) 43 hemichannel-binding antibodies and uses thereof
WO2017190152A1 (en) 2016-04-29 2017-11-02 Ocunexus Therapeutics, Inc. Sustained release drug delivery devices
JOP20170170B1 (ar) 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
TWI911431B (zh) * 2017-03-01 2026-01-11 英商梅迪繆思有限公司 抗rsv單株抗體配製物
US11603407B2 (en) * 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
MA49960A (fr) * 2017-08-25 2021-06-02 Omeros Corp Formulations d'anticorps inhibiteurs de masp-2 hautement concentrées à faible viscosité, kits et méthodes de traitement de sujets souffrant d'un syndrome hémolytique atypique
CN116854816A (zh) * 2018-04-02 2023-10-10 阿拉玛布治疗学股份有限公司 连接蛋白43抗体及其用途
MX2021005708A (es) * 2018-11-16 2021-09-21 Bristol Myers Squibb Co Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos.
AU2020219112A1 (en) * 2019-02-04 2021-08-26 Alamab Therapeutics, Inc. Connexin 43 antibodies and use thereof
CA3156812A1 (en) * 2019-10-02 2021-04-08 Alamab Therapeutics, Inc. Anti-connexin antibody formulations
IL300245A (en) 2020-07-31 2023-03-01 Alamab Therapeutics Inc Anti-connexin antibody formulations

Also Published As

Publication number Publication date
CA3190474A1 (en) 2022-02-03
US20240309085A1 (en) 2024-09-19
EP4188544A4 (en) 2024-09-11
US20220033492A1 (en) 2022-02-03
US11912764B2 (en) 2024-02-27
KR20230042744A (ko) 2023-03-29
WO2022026914A1 (en) 2022-02-03
EP4188544A1 (en) 2023-06-07
JP2023537316A (ja) 2023-08-31
IL300245A (en) 2023-03-01
CN116234576A (zh) 2023-06-06

Similar Documents

Publication Publication Date Title
US11912764B2 (en) Anti-connexin antibody formulations
RU2731418C2 (ru) Стабильный фармацевтический препарат на основе антитела к pd-1 и его применение в медицине
US20260049132A1 (en) Anti-connexin antibody formulations
AU2013255413C1 (en) Pharmaceutical formulations of TNF-alpha antibodies
EP3506886B1 (en) Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods
US20110070225A1 (en) Beta antibody parenteral formulation
JP2020518587A (ja) 抗lag3抗体の製剤および抗lag3抗体と抗pd−1抗体との共製剤
MX2014013434A (es) Formulaciones liofilizadas y acuosas de anticuerpo anti-cd40.
US20170137535A1 (en) Anti-factor d antibody formulations
KR20220124208A (ko) 프로그램된 세포 사멸 수용체1 항체 제제 및 그 용도
EP4094777A1 (en) Recombinant fully human anti-tigit monoclonal antibody preparations, preparation method therefor and use thereof
KR20240100493A (ko) 항-cd22 항체의 수성 제제 및 이의 용도
HK40077586A (en) Anto-connexin antibody formulations
EP4548931A1 (en) Anti-pcsk9 antibody preparation and use thereof
US20230131324A1 (en) Formulations of anti-endothelial lipase antibodies
US20250108109A1 (en) Formulations comprising fab-peg
CN121490076A (zh) 一种稳定的抗人masp2单克隆抗体制剂
CN116887860A (zh) 抗il5r抗体配制品
HK40103088A (en) Anti-il5r antibody formulations
OA17126A (en) Pharmaceutical formulations of TNF-alpha antibodies